REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
2 hedge funds and large institutions have $33K invested in REGENERX BIOPHARMACEUTICALS in 2015 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
43% more capital invested
Capital invested by funds: $23K → $33K (+$10K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BMO
Beck Mack & Oliver
New York
|
+$7K |
Top Sellers
RGN Hedge Fund Activity: Q3 2015 in Review
2 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q3 2015, worth a combined $33K — up 43% from $23K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new RGN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Beck Mack & Oliver, opening a new position worth an estimated $7K.
- 2 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q3 2015, up from 1 in Q2 2015.
- Funds reported $33K of REGENERX BIOPHARMACEUTICALS stock for Q3 2015, up 43% quarter-over-quarter.
- 1 fund opened new REGENERX BIOPHARMACEUTICALS positions in Q3 2015 and 0 closed out, a net change of +1 holder.
- The largest REGENERX BIOPHARMACEUTICALS buyer in Q3 2015 was Beck Mack & Oliver, an estimated $7K added.
Based on aggregated 13F filings for Q3 2015.